logo-loader
AIM:AVCT

Avacta Group PLC

Market:
AIM
Market Cap:
£283.63 m
Price
114.00 GBX
Change
5.56%
52 weeks high
215.36
52 weeks low
12.62

In brief

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.

Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.

Deep dive We explore the investor case for growth companies

Snapshot

Avacta is using affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Anatomy of a winner: picking a coronavirus success stock

While the pandemic has roiled global markets, and society, since March, investors may have found success among the lockdown if they had parked their cash in a number of sectors and industries...

18 hours, 11 minutes ago